je.st
news
Home
› Afraxis, Inc. And Servier Announce A Collaboration On ESP Platform For Drug Discovery In Central Nervous System Disorders
Afraxis, Inc. And Servier Announce A Collaboration On ESP Platform For Drug Discovery In Central Nervous System Disorders
2013-05-01 06:34:08| drugdiscoveryonline News Articles
Afraxis, Inc. ("Afraxis") and Institut de Recherches Servier ("Servier") announced a non-exclusive platform collaboration using Afraxis' Enhanced Spine Platform (ESP) Technology for the discovery of drugs to treat central nervous system (CNS) disorders
Tags: system
central
drug
platform
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||